Which of the following is not a pharmacological propey of Repaglinide?
**Core Concept**
Repaglinide is a **meglitinide** analog that acts as a **short-acting insulin secretagogue**, used in the management of type 2 diabetes mellitus. It works by closing **ATP-sensitive potassium channels** in the pancreatic beta cells. This action depolarizes the cells, opening **voltage-dependent calcium channels**, which increases intracellular calcium and stimulates insulin release.
**Why the Correct Answer is Right**
Given the correct answer is not provided, let's discuss the general properties of Repaglinide. Repaglinide increases insulin secretion by closing **ATP-sensitive potassium channels**. It has a rapid onset and short duration of action, making it suitable for controlling postprandial glucose spikes.
**Why Each Wrong Option is Incorrect**
**Option A:** Without the specific option text, we cannot directly address why it is incorrect. Normally, we would explain how the option does not align with Repaglinide's properties, such as its mechanism of action or effects on glucose metabolism.
**Option B:** Similarly, without the text, we cannot provide a detailed explanation for why this option is incorrect. Typically, we'd discuss how Repaglinide's pharmacokinetics or pharmacodynamics do not match the description in Option B.
**Option C:** Again, lacking the specific option details, we cannot directly refute it. Usually, we would clarify how Repaglinide's known properties, like its impact on insulin secretion or its use in clinical practice, contradict the statement in Option C.
**Option D:** This option would be analyzed in the context of Repaglinide's known effects, such as its rapid action, short half-life, and specific indications, to explain why it does not fit as a description of the drug.
**Clinical Pearl / High-Yield Fact**
Repaglinide is particularly useful for patients with type 2 diabetes who have irregular meal schedules because it can be taken just before meals to manage postprandial glucose levels effectively. Its short duration of action reduces the risk of hypoglycemia when a meal is missed.
**Correct Answer:** Correct Answer: D. Decreases insulin secretion.